Steve Harvey/LinkedIn
Sep 19, 2025, 06:06
Aspirin as Precision Medicine? Steve Harvey Highlights Evidence for PIK3-Mutated Colorectal Cancer Patients
Steve Harvey, CEO of Camena Bioscience, shared a post on LinkedIn:
“A very interesting study indicates that Aspirin could be a precision medicine for colorectal cancer.
The study, which was publicised in the New England Journal of Medicine, studied 3500 patients with colorectal cancer.
~40% of those patients had mutations in genes associated with the PIK3 signalling pathway.
Those patients with the PIK3 associated mutations and taking aspirin, were 55% less likely to have the cancer return than those on placebo.
P.s. I’ll add the Guardian article to the comments.”
You can read the full article here.
More posts featured in Hemostasis Today.
-
Jan 7, 2026, 13:57Joshua Muia: Delighted to Welcome X. Long Zheng for a Versiti Seminar on TTP
-
Jan 7, 2026, 13:40Marilena Vrana Invites You to IPPC2026
-
Jan 7, 2026, 13:32Carlos Villa Joins Versiti Blood Research Institute
-
Jan 7, 2026, 13:21Bartosz Hudzik: New Evidence on “Aspirin Failure” After Ischemic Stroke
-
Jan 7, 2026, 08:50Fahad Khaliq on When is Ticagrelor Preferred Over Other Antiplatelets
-
Jan 7, 2026, 06:41Zain Khalpey on AI Driven Risk Prediction for Optimization of Anticoagulation in LVAD
-
Jan 7, 2026, 05:47Michael Makris: The Wakley Prize Essay Published in Today’s Lancet is an Excellent Read
-
Jan 7, 2026, 05:36Pierre F Sabouret Shares A Study on the Risk of Cardiovascular Death in SIDs
-
Jan 7, 2026, 05:15Glaivy Batsuli Reflects on ASH25